Intelligence · Clinical Development
Pipeline search results
Programs matching “dexmedetomidine” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 65 pipeline programs matching "dexmedetomidine" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
DEXMEDETOMIDINE , 18F-DPA-714
Pari Pharma GmbH
Patients who survive a COVID ARDS in intensive care must be weaned off invasive mechanical ventilation as quickly as possible. 60% of these patients present with intensive care delirium, a serious event that causes excess mortality and potential acute and late complications, since 30% of patients who present with delirium develop cognitive sequelae. Severe neuroinflammation is considered to be one of the main pathophysiological mechanisms causing delirium during ventilatory weaning. In addition to its sedative properties, dexmedetomidine has neuroprotective effects. In certain experimental models, it reduces cerebral inflammation by acting directly on the microglial phenotype. The role of this chronic neuroinflammatory state on cognitive capacity and reserve is beginning to emerge in the literature, regardless of the initial stress (surgery, head injury or Alzheimer's-type dementia), and is therefore capable of influencing patients' quality of life. The assessment of this neuroinflammation using non-invasive tools would appear to be of prime importance in the management of post-COVID neuro injured patients, as well as the evaluation of potential neuroprotective agents such as dexmedetomidine.
1 trial -
Dexmedetomidine Hcl 100 Mcg/mL Inj
Hospital Authority, Hong Kong
Congenital Heart Disease in Children
1 trial -
PEDIADEX
Tour Hekla
Impact on delirium of the use of DEXmedetomidine as first-line sedation in PEDIAtric intensive care:
1 trial -
SEVOFLURANE, DEXMEDETOMIDINE HYDROCHLORIDE
The George Institute
Children under the age of 2 years having surgery lasting at least 2 hours
1 trial -
Sublingual film containing Dexmedetomidine (BXCL501)
BioXcel Therapeutics
Agitation Associated With Bipolar Disorder
1 trial -
Sublingual film containing dexmedetomidine (BXCL501)
BioXcel Therapeutics
Agitation
1 trial -
Caudal Dexmedetomidine
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Inguinal Hernia
1 trial -
Dexmedetomidine
BioXcel Therapeutics
Opioid Withdrawal
1 trial -
Dexmedetomidine
COGNITION THERAPEUTICS INC
Alzheimer Disease
1 trial -
Dexmedetomidine injection
Sana Biotechnology
Post Spinal Shivering
1 trial -
Dexmedetomidine sublingual film
BioXcel Therapeutics
Delirium
1 trial -
Sublingual film containing Dexmedetomidine
BioXcel Therapeutics
Agitation,Psychomotor
1 trial -
Dexmedetomidine
The First People's Hospital of Lianyungang
Heart Injuries
1 trial -
Dexmedetomidine
The First People's Hospital of Lianyungang
Cesarean Section, Affecting Fetus or Newborn
1 trial -
Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg
BioXcel Therapeutics
Alcohol Use Disorder (AUD)
1 trial -
Sublingual film containing BXCL501 (Dexmedetomidine)
BioXcel Therapeutics
Agitation
1 trial -
0.3% ropivacaine and 50 μg dexmedetomidine
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Free Flap Reconstruction
1 trial -
Dexmedetomidine
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Lower Limb Fracture
1 trial -
Dexmedetomidine
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Chronic Post-Surgical Pain
1 trial -
Dexmedetomidine
The First People's Hospital of Lianyungang
Elderly
3 trials -
Dexmedetomidine
The First People's Hospital of Lianyungang
Renal Function
1 trial -
Dexmedetomidine
The University of Hong Kong
Anxiety, Separation
1 trial -
Dexmedetomidine
Hospital Authority, Hong Kong
Thyroid Diseases
1 trial -
Dexmedetomidine
The First People's Hospital of Lianyungang
Breast Cancer
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.